EUVIMEDEUVIMED entdecken
Multizentrische Studie

Spike Protein Genetic Evolution in Patients at High Risk of Severe Coronavirus Disease 2019 Treated by Monoclonal Antibodies

Valentin Leducq iD, Karen Zafilaza, Antoine Fauchois, Emna Ghidaoui, Sophie Sayon, Céline Dorival, Marie-Laure Meledje, Clovis Lusivika-Nzinga, Youri Yordanov, Guillaume Martin-Blondel, Fabrice Carrat iD, Anne-Geneviève Marcelin und 1 weitere

The Journal of Infectious Diseases · 15.05.2024 · 229 (5) · 1341-1351

DOI: 10.1093/infdis/jiad523 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 23.11.2023. Verfasst von Valentin Leducq und 12 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne Université, Inserm, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitair…. Hauptthemen laut MEDLINE: Spike Glycoprotein, Coronavirus, SARS-CoV-2, COVID-19, Antibodies, Monoclonal. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: ANRS, MIE, Ministère des Solidarités et de la Santé and Ministère de l'Enseignement Supérieur, de la Recherche et de l'Innovation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

High-risk patients, often immunocompromised and not responding to vaccine, continue to experience severe coronavirus disease 2019 (COVID-19) and death. Monoclonal antibodies (mAbs) were shown to be effective to prevent severe COVID-19 for these patients. Nevertheless, concerns about the emergence of resistance mutations were raised.

Methods

We conducted a multicentric prospective cohort study, including 264 patients with mild to moderate COVID-19 at high risk for progression to severe COVID-19 and treated early with casirivimab/imdevimab, sotrovimab, or tixagevimab/cilgavimab. We sequenced the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome during follow-up and searched for emerging spike mutations.

Results

Immunocompromised patients have a 6-fold increased risk of developing mutations, which are associated with a prolonged duration of viral clearance but no clinical worsening. Emerging P337S/R/L/H, E340D/K/A/Q/V/G, and K356T/R substitutions in patients treated with sotrovimab are associated with higher viral RNA loads for up to 14 days post–treatment initiation. Tixagevimab/cilgavimab is associated with a 5-fold increased risk of developing mutations. R346K/I/T/S and K444R/N/M substitutions associated with tixagevimab/cilgavimab have been identified in multiple SARS-CoV-2 lineages, including BQ.1 and XBB.

Conclusions

The probability of emerging mutations arising in response to mAbs is significant, emphasizing the crucial need to investigate these mutations thoroughly and assess their impact on patients and the evolutionary trajectory of SARS-CoV-2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spike Glycoprotein, CoronavirusSARS-CoV-2COVID-19Antibodies, MonoclonalMutationCOVID-19 Drug TreatmentHumansProspective StudiesFemaleMaleMiddle AgedAgedEvolution, MolecularAntibodies, Monoclonal, HumanizedImmunocompromised HostAdult

Stichwörter der Autor:innen

COVID-19SARS-CoV-2immunocompromisedmonoclonal antibodiesresistance mutations

Substanzen

Spike Glycoprotein, CoronavirusAntibodies, MonoclonalAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Sorbonne Université, Inserm, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Laboratoire de virologie, Paris, Fr…
  • Sorbonne Université, Inserm, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Epidémiologie clinique des maladies virales chroniques (CLEPIVIR), Paris, France.
  • Sorbonne Université, Inserm, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, Service d'Accueil des Urgences, Paris, France.
  • Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Toulouse, Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), Inserm, Université Toulouse III, Toulouse, Franc…
  • Sorbonne Université, Inserm, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Département de Santé Publique, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, Paris, France.

ORCID-Profile: Valentin Leducq, Fabrice Carrat

Förderung

  • ANRS
  • MIE
  • Ministère des Solidarités et de la Santé and Ministère de l'Enseignement Supérieur, de la Recherche et de l'Innovation
  • Ministère des Solidarités et de la Santé and Ministère de l’Enseignement Supérieur, de la Recherche et de l’Innovation

Zitieren

APA

Leducq, V., Zafilaza, K., Fauchois, A., Ghidaoui, E., Sayon, S., Dorival, C., Meledje, M. L., Lusivika-Nzinga, C., Yordanov, Y., Martin-Blondel, G., Carrat, F., Marcelin, A. G., & Soulie, C. (2024). Spike Protein Genetic Evolution in Patients at High Risk of Severe Coronavirus Disease 2019 Treated by Monoclonal Antibodies. The Journal of Infectious Diseases, 229(5), 1341-1351. https://doi.org/10.1093/infdis/jiad523

Vancouver

Leducq V, Zafilaza K, Fauchois A, Ghidaoui E, Sayon S, Dorival C, et al. Spike Protein Genetic Evolution in Patients at High Risk of Severe Coronavirus Disease 2019 Treated by Monoclonal Antibodies. The Journal of Infectious Diseases. 2024;229(5):1341-1351. doi:10.1093/infdis/jiad523

BibTeX
@article{Leducq2024,
  author = {Leducq, Valentin and Zafilaza, Karen and Fauchois, Antoine and Ghidaoui, Emna and Sayon, Sophie and Dorival, Céline and Meledje, Marie-Laure and Lusivika-Nzinga, Clovis and Yordanov, Youri and Martin-Blondel, Guillaume and Carrat, Fabrice and Marcelin, Anne-Geneviève and Soulie, Cathia},
  title = {Spike Protein Genetic Evolution in Patients at High Risk of Severe Coronavirus Disease 2019 Treated by Monoclonal Antibodies},
  journal = {The Journal of Infectious Diseases},
  year = {2024},
  volume = {229},
  number = {5},
  pages = {1341--1351},
  doi = {10.1093/infdis/jiad523}
}
Kostenlos starten →